Monash University has entered into a licensing agreement with CSL, marking a significant outcome that reflects the University’s ambition and growing success in research translation and industry engagement. As Australia’s largest biotechnology company, CSL plays a central role in the national life sciences ecosystem.
Under the agreement, CSL has in-licensed a Monash-originated antibody therapeutic programme focused on immune-mediated diseases, following a research collaboration established through CSL’s external innovation efforts to accelerate scientific discoveries.
Immune-mediated diseases can occur when an immune response has an adverse effect on your body instead of, or in addition to, defending it.
The programme originated in the laboratory of Associate Professor Remy Robert at the Monash Biomedicine Discovery Institute and was selected by CSL for an industry-funded collaboration designed to accelerate promising academic research toward development. Following completion of the research collaboration, CSL elected to exercise its option to license the programme, with the licence executed in December 2025.
Dr Ingmar Wahlqvist, Acting Chief Commercialisation Officer at Monash University, said the agreement demonstrates Monash’s ambition and strength in working with industry.
“This licensing agreement is a strong example of how intellectual property developed at Monash can progress toward potential new therapies for patients, while also supporting a sustainable model for reinvestment in future research,” Dr Wahlqvist said.
Image caption- L to R: Dr Michael Wilson, Senior Vice President and Head of Research at CSL; Associate Professor Remy Robert from the Monash Biomedicine Discovery Institute; and Dr Jarrat Jordan, Research Therapeutic Area Lead, Immunology at CSL
